An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

ClinicalTrials.gov ID: NCT03813407

Public ClinicalTrials.gov record NCT03813407. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID: NCT03813407
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 140 participants

Conditions and interventions

Conditions

Hyperkalaemia

Interventions

Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase Drug
Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1) Drug
Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2) Drug
Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3) Drug
Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level Drug

Drug

Eligibility (public fields only)

Age range: 0 Years to 18 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 1, 2019
Primary completion: Feb 20, 2030
Completion: Feb 20, 2030
Last update posted: May 14, 2026

2019 – 2030

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35233	Recruiting
Research Site	Atlanta	Georgia	30322	Withdrawn
Research Site	Baltimore	Maryland	21287	Recruiting
Research Site	Grand Rapids	Michigan	49503	Withdrawn
Research Site	St Louis	Missouri	63104	Withdrawn
Research Site	Hackensack	New Jersey	07601	Completed
Research Site	New York	New York	10029	Withdrawn
Research Site	Stony Brook	New York	11794	Withdrawn
Research Site	Charlotte	North Carolina	28207	Withdrawn
Research Site	Winston-Salem	North Carolina	27157	Withdrawn
Research Site	Akron	Ohio	44308	Completed
Research Site	Cincinnati	Ohio	45229	Recruiting
Research Site	Columbia	South Carolina	29203	Recruiting
Research Site	Morgantown	West Virginia	26506-7900	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03813407, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 14, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03813407 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →